Erik Huneker
Co-Founder
Diabeloop
Diabeloop offers an AI‑driven hybrid closed‑loop system that automates insulin delivery for people with type 1 diabetes. Its DBLG1 algorithm continuously processes real‑time glucose data from a CGM and contextual inputs to calculate and deliver personalized insulin doses via compatible pumps or connected pens, reducing the daily decision burden. The platform also supports integration with devices such as Dexcom G7 and ViCentra Kaleido and is expanding to smartphone and wearable applications.
- Artificial Intelligence
- Digital Health
- Hardware
- Healthcare Technology
- Medical Devices
Updated 5 months ago
Funding
Raised to date
$16.3MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
People with type 1 diabetes must make dozens of insulin dosing decisions each day, manually interpreting continuous glucose monitor data and adjusting for meals, activity, and other factors. This high cognitive load leads to frequent dosing errors, suboptimal glycemic control, and reduced quality of life.
Solution
Diabeloop provides an AI‑driven hybrid closed‑loop system that automates insulin delivery for type 1 diabetes. The DBLG1 algorithm runs on a dedicated terminal that receives glucose readings from a continuous glucose monitor (CGM) via Bluetooth every five minutes, processes patient‑specific parameters and contextual inputs (e.g., meals, exercise), and calculates the appropriate insulin dose. The system integrates with compatible insulin pumps or, in development, with connected insulin pens and smart devices, delivering the dose without user intervention. By continuously adapting to real‑time glucose trends, the platform reduces the mental burden of diabetes management while maintaining personalized therapy. Ongoing development extends the solution to smartphone‑based applications and wearable form factors, broadening access to automated insulin therapy.
Target Audience
Primary customers are adults and adolescents with type 1 diabetes who use insulin pumps or are transitioning to automated insulin delivery, as well as healthcare providers and diabetes clinics seeking advanced closed‑loop therapy solutions.
Features
- Auto‑learning DBLG1 algorithm that personalizes insulin dosing based on real‑time CGM data and user inputs
- Dedicated terminal with Bluetooth® connectivity to receive glucose measurements every five minutes
- Hybrid closed‑loop operation compatible with approved insulin pumps and upcoming connected insulin pens
- Real‑time dose calculation and delivery without manual user action, lowering decision fatigue
- Planned extensions to smartphone apps, smartwatches, and other wearables for broader device compatibility
- Integration with partner devices such as Dexcom G7 CGM and ViCentra Kaleido insulin‑patch pump